Disease relevance of Ventavis

• We investigated the cytoprotective effects of verapamil, a Ca channel blocker, and of iloprost (ZK 36374), a stable prostacyclin analogue, on ischemia/reperfusion (I/R) injury in Wistar albino rat kidneys that were subjected to 60 min of warm ischemia and reperfusion [1].
• The effect of the stable prostacyclin analogue ZK 36374 on experimental coronary thrombosis in the pig [2].
• These results indicate that ZK 36374 possesses therapeutic potential in vascular disease including that affecting the coronary vessels [3].
• Iloprost (ZK 36374, a stable analog of prostaglandin I2, 25 ng/kg body weight) decreased the mortality rate from 100% to 50% [4].
• BACKGROUND: Iloprost (Ventavis) inhalation solution is approved in doses of 2.5 mug and 5.0 mug for treatment of pulmonary arterial hypertension (World Health Organization group I) in patients with New York Heart Association class III or IV symptoms, delivered with 2 Adaptive Aerosol Delivery (AAD) systems: Prodose and I-neb [5].

High impact information on Ventavis

• The appearance of inhibitory activity could be blocked by the addition of the prostacyclin analogue ZK 36374 at any time during platelet activation [6].
• This suggested an important role for phosphatidylinositol hydrolysis in mediating ILP and c-PGI(2) effects but not CCP in RCCD [7].
• Relatively unactivated platelets (< 15% expressing prebound fibrinogen) were prepared from acidified citrated platelet rich plasma (cPRP) by single centrifugation with 50 nM stable prostacyclin derivative ZK 36374 and resuspended in Tyrodes-albumin at 5 x 10(4) cells microliter-1 [8].
• Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man [9].
• To assess whether the administration of the stable prostacyclin-mimetic ZK 36374 (iloprost) protects the myocardium in a dose-dependent manner against ischaemia and reperfusion, isolated rabbit hearts were infused with three different concentrations of iloprost: 2.7, 27 and 270 nM [10].

Chemical compound and disease context of Ventavis

• Effect of verapamil and iloprost (ZK 36374) on endothelin release after mesenteric ischemia-reperfusion injury [11].

Biological context of Ventavis

• Pulmonary vasodilatation induced by ciloprost was greater than that by NO but with the same side effects as nitroglycerin on systemic variables [12].
• ZK 36374 alone consistently inhibited platelet aggregation and calcium mobilization in response to ADP and thrombin, in a dose-dependent fashion [13].
• This prolongation of TOT was not due to the lower blood pressure in the ZK 36374 group, as dihydralazine in a dose that lowered arterial blood pressure to the same extent had no effect on TOT (32 +/- 4 minutes, n = 4) [2].
• CONCLUSIONS: Alveolar deposition of Ventavis in NHBD lungs before preservation significantly improves dynamic lung compliance and represents an important strategy for improvement of preservation quality and expansion of warm ischemic intervals [14].
• Intestinal motility was strongly reduced by both PGI2 and Ciloprost [15].

Anatomical context of Ventavis

• Iloprost (ZK 36374) enhances recovery of regional myocardial function during reperfusion after coronary artery occlusion in the pig [16].
• The histopathologic investigation of the small intestine after giving ZK 36374 and UK 38345 together revealed minimal changes [17].
• The effect of Iloprost (ZK 36374) on isolated and transplanted pancreatic islet cells [18].
• Pharmacological properties of Ciloprost, a stable prostacyclin analogue, on the gastrointestinal tract [15].
• In the same experimental design continuous i.v. infusion of Ciloprost and PGI2 caused 50% reduction in gastric acid output with doses of 80 and 24 micrograms/(kg x h), respectively [15].

Associations of Ventavis with other chemical compounds

• In this study, while ZK 36374 significantly lowered the alkaline phosphatase and creatine phosphokinase values two hours after mesenteric arterial occlusion when compared with the control group (p less than 0.005), UK 38485 did not induce any change [17].
• The effects of ZK 36374, a prostacyclin analogue and UK 38485, a thromboxane synthetase inhibitor were studied in guinea pigs after performing mesenteric arterial occlusion [17].

Gene context of Ventavis

• Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6 [19].
• Iloprost (IP) stimulation (1 microM, 2 h) of Flag-epitope-tagged human IP prostanoid receptor (FhIPR) expressed in HEK293 cells resulted in specific decrease of endogenous G(s)alpha protein in detergent-insensitive, caveolin-enriched, membrane domains (DIMs) [20].
• Our data indicate that (i) long-term agonist stimulation of IP prostanoid receptor is associated with preferential decrease of its cognate G protein G(s)alpha from membrane domains; receptor level is unchanged [20].

Analytical, diagnostic and therapeutic context of Ventavis

• Quantification of extracorporeal platelet deposition in cardiopulmonary bypass: effects of ZK 36374, a prostacyclin analogue [21].
• The effects of ZK 36374, a prostacyclin analogue, on deposition of platelets in the oxygenator and atrial line filter were also investigated [21].
• In this study, the effects of iloprost (ZK 36374) and NDGA on warm ischemia and reperfusion injury in rat liver were investigated [22].
• In groups 2 and 3, 100 mug Ventavis were aerosolized over 30-min using an ultrasonic nebulizer (Optineb) [14].
• Lungs were then retrogradely preserved with Perfadex and stored for 3-h. After left lung transplantation and contralateral lung exclusion, grafts were reperfused for 6-h. Only in group 3, another dose of 100 mug Ventavis was aerosolized during the first 30-min of reperfusion [14].

References